Skip to main content

Research News

 

Clinical courses

  • Merck breast cancer medicine meets trial endpoint

    Merck known as MSD outside of the United States and Canada, announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete response (pCR) rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen in patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.

  • Gene Mutation May Explain why Some Don’t Get Sick from COVID-19

    People who contract COVID-19 but never develop symptoms the so-called super dodgers may have a genetic ace up their sleeve. They’re more than twice as likely as those who become symptomatic to carry a specific gene variation that helps them obliterate the virus, according to a new study led by UC San Francisco researchers. 

  • Machine Learning : Artificial Neural Networks Localize Extrasystoles

    Additional heartbeats from cardiac chambers, so-called ventricular extrasystoles, may be associated with severe diseases. Researchers at Karlsruhe Institute of Technology (KIT) use machine learning for their non-invasive localization. This may facilitate and improve future diagnosis and therapy. The researchers use artificial neural networks trained with synthetic data from a realistic simulation model. They report in Artificial Intelligence in Medicine.

  • A Common Diabetes Drug Has a Surprising Side Gig : Muscle Protector

    University of Utah Health researchers have discovered that Metformin, a common drug that’s been used in diabetes treatment for more than half a century, has surprising applications on a cellular level. It can target “zombie-like cells,” called senescent cells, which impact muscle function. Senescent cells secrete factors associated with inflammation that may underlie fibrotic tissue, a hardening or scarring of tissues. Metformin also reduces muscle atrophy. Their findings published in Aging Cell.

  • Unraveling a protein that may inspire a new biotechnology tool

    Scientists have unraveled the step-by-step activation process of a protein with a deep evolutionary history in all domains of life, opening the door to harnessing its functions for use as a biotechnology tool.

    The protein belongs to the “superfamily” of Argonaute proteins, which previous research has suggested to be involved in gene silencing, a fundamental process known as RNA interference.

  • Asprius Lifesciences developed treatment for Diabetic Neuropathy

    Asprius Lifesciences has announced that it has developed treatment for Diabetic Neuropathy, a condition that results in nerve damage in peripheral areas of the body. The company said it has already filed a patent for the Fixed-Dose Combination that holds promise in treating peripheral neuropathy.

  • WHO releases new guidance to improve testing and diagnosis of sexually transmitted infections

    The World Health Organization (WHO) is sharing its latest guidance on sexually transmitted infections (STI) at the STI & HIV 2023 World Congress taking place in Chicago, the United States of America, on 24-27 July 2023. With STIs on the rise, WHO is calling for better access to testing and diagnostic services. At the congress, WHO will also discuss its latest STI research agenda and antimicrobial resistance (AMR) in gonorrhoea.

  • New study shows anti-inflammatory drugs as a promising target for Alzheimer’s disease

    A recent study from the lab of the University of Kentucky’s Sanders-Brown Center on Aging Director Linda Van Eldik, Ph.D., has been published in PLOS ONE. The work centers around the idea that various anti-inflammatory drugs could be effective treatments for Alzheimer’s disease (AD). This study focused on a protein known as p38. Many labs have been working with this protein as a potential target for drug development to treat Alzheimer’s disease and other conditions with neuroinflammatory dysfunction.

  • ChatGPTs responses to healthcare related queries are nearly indistinguishable

    ChatGPT’s responses to people’s healthcare-related queries are nearly indistinguishable from those provided by humans, a new study from NYU Tandon School of Engineering and Grossman School of Medicine reveals, suggesting the potential for chatbots to be effective allies to healthcare providers’ communications with patients.

    An NYU research team presented 392 people aged 18 and above with ten patient questions and responses, with half of the responses generated by a human healthcare provider and the other half by ChatGPT.

  • Birth-control pills affect the body's ability to regulate stress : Researchers

    Women have used birth-control pills since the 1960s, but researchers still do not know everything about the body's complex reaction to the small, hormone-laden pill.

    Researchers from Aarhus University and the United States have studied the stress response of 131 young women when having a blood sample taken. Some of the women were on birth-control pills, while others were not. The researchers specifically measured the levels of the stress hormone ACTH in the women’s blood.

Subscribe to Research News